JOIN this TEC Validation Project™: New alternative to animal testing in human cardiac muscle cells

 

JOIN this TEC Validation Project™: Validate a new alternative to animal testing in human cardiac muscle cells

Together with Axiogenesis, we are excited to announce a new, free opportunity for drug safety professionals in the pharmaceutical industry. This unique opportunity will provide participants with the benefit of assessing, in a pre-competitive manner, a novel and disruptive safety technology, which could further optimize internal drug development processes.

We welcome new industry members – as we have recently secured funding which allows biopharma companies to join the consortium (upon approval), without having to pay an annual membership fee. SIGN UP to this WEBINAR, to learn more.

 

(Even if you cannot attend, register for the event and we will send you a copy of the recording.)

Axiogenesis has developed a cost-effective, translational alternative for evaluating toxicity in human cardiac muscle cells very early during compound series selection. They have developed Cor.4U® human cardiomyocytes, derived from Induced Pluripotent Stem Cells (IPSCs), ‘non-controversial’ stem cells generated from adult somatic cells. Cor.4U Cardiomyocytes have a variety of applications, including being used to prioritize compound series before SAR by measuring characteristics such as beat rate, amplitude and more.

Axiogenesis has also developed an impedance assay, called CardioEffect, which applies Cor.4U cardiomyocytes to predictively assess cardiotoxicity more quickly and cost-effectively than common in vivo assays.

Interested in getting involved in this TEC Validation Project™ with the SafeTEC Consortium?

We are seeking new Biotech & Pharma corporate members for the SafeTEC consortium, along with others involved in pre-clinical safety testing for small molecules.

– Axiogenesis is hosting a webinar for members to discuss the cells, assays, a Large Pharma case study, and the needs of the drug discovery & development community.

– Axiogenesis will provide sufficient cells for the project. The assay will be repeated and blinded at one of our Consortium member sites.

– These results will be compared to in vivo/clinical data and discussed amongst Consortium members.

Who should join the Webinar and TEC Validation Project™?

– Medicinal Chemists seeking early feedback on the potential cardiotoxicity of chemical series

– Biologists and Assay Developers supporting Med Chem during Lead Selection

– Toxicology and Safety Researchers

– Senior Managers in early drug discovery

CLICK HERE to register for the webinar “TEC Validation Project™: New alternative to animal testing in human cardiac muscle cells!”

 

(Even if you cannot attend, register for the event and we will send you a copy of the recording.)

 

FREE ANNUAL MEMBERSHIP:

If you want to join the SafeTEC consortium and be involved with 15+ more activities like this one, let us know or check out our website here:

http://www.onemillionsolutionsinhealth.org/collaborate/signature-square/drug-safety-leaders-talk-about-safetec/

Download our flyer here to see the list of phenomenal scientific opportunities under evaluation in the consortium over the next 18 months.

We look forward to having you help us move forward as we innovate the discovery of safer and more efficacious drugs!!

 

---

PANELISTS
	SPEAKER: Brian Murphy, MBA Director North America Sales & Marketing Axiogenesis
	SPEAKER: Greg Luerman, PhD Technical Director, North America Axiogenesis
	MODERATOR: Dawn Van Dam President & CEO One Million Solutions in Health™